KemPharm Presents Study Highlighting Patient-Friendly Dosing Properties of KP415 at the 66th Annual American Academy of Child & Adolescent Psychiatry Meeting
October 22, 2019 16:15 ET
|
KemPharm
Data Demonstrate that KP415 Can Be Administered without Regard to Food; Can Be Mixed into Foods or Drink CELEBRATION, Fla., Oct. 22, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a...
KemPharm Provides Updates Regarding its Board of Directors
September 20, 2019 17:00 ET
|
KemPharm
CELEBRATION, Fla., Sept. 20, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced...
KemPharm to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Diseases
September 17, 2019 08:30 ET
|
KemPharm
CELEBRATION, Fla., Sept. 17, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced...
KemPharm to Present at the 21st Annual Global Investment Conference, Sponsored By H.C. Wainwright & Co.
September 05, 2019 07:30 ET
|
KemPharm
CELEBRATION, Fla., Sept. 05, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today...
KemPharm Announces Entry into Definitive Collaboration and License Agreement for its ADHD Candidates, KP415 and KP484, with an Affiliate of Gurnet Point Capital
September 04, 2019 08:00 ET
|
KemPharm
Up to a Total of $493 Million in Upfront, Sales and Development Milestone Payments, as well as Royalties on Net Sales KemPharm Will Host a Conference Call and Live Audio Webcast with Slide...
KemPharm Reports Second Quarter 2019 Results
August 13, 2019 17:00 ET
|
KemPharm
CELEBRATION, Fla., Aug. 13, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today...
KemPharm Reports First Quarter 2019 Results
May 14, 2019 16:05 ET
|
KemPharm
Development & Regulatory Highlights: Completed KP415 Pre-NDA Meeting with FDAProvided Update on APADAZ® Formulary AdoptionAnnounced FDA Approval of sNDA for Two Additional Strengths of APADAZ ...
KemPharm Completes KP415 Pre-NDA Meeting with FDA
April 11, 2019 16:17 ET
|
KemPharm
KP415 NDA Filing Anticipated in Late Q2 or Early Q3 2019 Conference Call Scheduled for Today, Thursday, April 11, 2019 at 5:00 p.m. ET CELEBRATION, Fla., April 11, 2019 (GLOBE NEWSWIRE) --...
KemPharm Provides Update on APADAZ® Formulary Adoption
March 13, 2019 07:30 ET
|
KemPharm
Conference Call Scheduled for Today, Wednesday, March 13, 2019 at 8:30 a.m. ET Highlights: According to MMIT estimates, the authorized generic for APADAZ has unrestricted formulary access for 91% of...
KemPharm to Present at Upcoming Investor Conferences
March 05, 2019 07:30 ET
|
KemPharm
CELEBRATION, Fla., March 05, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today...